<DOC>
	<DOCNO>NCT00288561</DOCNO>
	<brief_summary>Ranibizumab derive murine monoclonal anti- vascular endothelial growth factor ( VEGF ) antibody penetrate many retinal cell layer follow intravitreal injection . The present study direct towards assessment ranibizumab administer day combination verteporfin patient subfoveal CNV secondary ARMD</brief_summary>
	<brief_title>Study Ranibizumab Administered Conjunction With Photodynamic Therapy With Verteporfin Patients With Subfoveal Choroidal Neovascularization Age-Related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Patients 50 year age great provide write informed consent Patients subfoveal choroidal neovascularization lesion secondary AMD , either predominantly classic occult classic component Patients BCVA score 73 24 letter , inclusively , study eye use ETDRS ( approximately 20/40 20/320 ) Willing return schedule visit Patients BCVA &lt; 34 letter eye ( legally blind defined bilateral vision 20/200 less 34 letter ) Prior treatment study eye verteporfin , externalbeam radiation therapy , subfoveal focal laser photocoagulation , vitrectomy , transpupillary thermotherapy Previous participation clinical trial ( either eye ) involve antiangiogenic drug ( pegaptanib , ranibizumab , anecortave acetate , protein kinase C inhibitor , etc . ) Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>ARMD , ranibizumab , verteporfin</keyword>
</DOC>